# Vaxart to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25, 2026
Canonical URL: https://biopharmsignal.com/news/VXRT/vaxart-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-confer-ebeb787b
Ticker: VXRT
Company: Vaxart
Source: Vaxart
Published: 2026-02-18 13:00 EST
## Summary

Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of...

## Article Body
Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced that members of the management team will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place virtually February 25-26, 2026.

Presentation Details:

Date and Time: Wednesday, February 25 at 4:00pm ET Registration and Webcast: Click Here

The webcast will be available on the Company’s investor relations website at https://investors.vaxart.com for 30 days following the conclusion of the event.

The Company will participate in one-on-one meetings during the conference. Investors interested in meeting with management may reach out to their Oppenheimer representative.

About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

Contact

Vaxart Media and Investor Relations: FINN Partners IR@vaxart.com (646) 871-8481
## Recent Company News
- 2026-07-21 12:00 EST — [Vaxart to Participate in BTIG Biotechnology Conference 2026](https://biopharmsignal.com/news/VXRT/vaxart-to-participate-in-btig-biotechnology-conference-2026-f2702b19) — Source: Vaxart
- 2026-07-17 20:05 EST — [Vaxart Announces Results of Annual Meeting of Stockholders](https://biopharmsignal.com/news/VXRT/vaxart-announces-results-of-annual-meeting-of-stockholders-25ca999f) — Source: Vaxart
- 2026-07-06 20:01 EST — [Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine](https://biopharmsignal.com/news/VXRT/vaxart-reports-topline-12-month-safety-data-from-the-400-participant-sentinel-sa-ad993e0f) — Source: Vaxart
- 2026-07-01 20:00 EST — [Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements](https://biopharmsignal.com/news/VXRT/vaxart-enters-cooperation-agreement-with-stockholder-group-and-announces-board-a-2ed5b0dd) — Source: Vaxart
- 2026-06-26 12:00 EST — [Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY](https://biopharmsignal.com/news/VXRT/vaxart-publishes-presentation-urging-shareholders-to-vote-for-all-six-of-the-com-2bf27563) — Source: Vaxart
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)